Merck has announced that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place from October 15 to 18, 2025, in Paris, France.

The company will showcase multiple presentations highlighting advancements in HIV treatment and prevention. These include an oral presentation on weight and body composition outcomes at Week 48 from the phase-III trial (MK-8591A-052), comparing Doravirine/Islatravir [DOR/ISL (100mg/0.25mg)] with Bictegravir/Emtricitabine/Tenofovir Alafenamide [BIC/FTC/TAF (50mg/200mg/25mg)] for the once-daily treatment of adults with virologically suppressed HIV-1 infection on antiretroviral therapy.

Another poster presentation will feature findings on fasting lipids and insulin resistance at Week 48 from two phase-III trials (MK-8591A-051 and MK-8591A-052), evaluating DOR/ISL compared to baseline antiretroviral therapy or BIC/FTC/TAF in adults with virologically suppressed HIV-1 infection.

Additionally, an oral presentation will share 96-week safety and pharmacokinetics data from the phase-II trial (NCT05052996) of the investigational once-weekly oral combination of Islatravir with Lenacapavir (MK-8591D) for adults with virologically suppressed HIV-1 infection on BIC/FTC/TAF.

Finally, a poster presentation will present phase-I safety and pharmacokinetics data of MK-8527 (MK-8527-008), Merck’s investigational once-monthly pill for HIV pre-exposure prophylaxis (PrEP), in adults with moderate or severe renal impairment.

 “We are pleased to share new data from across our HIV pipeline at EACS 2025, including additional analyses from the phase-III programme of the investigational once-daily, two-drug treatment regimen, DOR/ISL, which is currently under review with the US Food and Drug Administration. By advancing multiple investigational agents for daily and weekly treatments and monthly oral prevention, we aim to give individuals new and different ways to treat and prevent HIV,” said Dr Luisa Stamm, Associate Vice President and HIV Section Head, Merck Research Laboratories.

This year at EACS, Merck will host a policy symposium “Ending the Epidemic in Europe: Policy Challenges and Opportunities” on October 16. It will also host a medical symposium “Optimisation of HIV Care” on October 17.